The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia.

It has been suggested that polycythemia vera (PV) could be preceded by an "early" phase of the disease (e-PV), in which the increase in the red cell parameters is lower than required for a PV diagnosis. In this study, we compared the clinicopathologic and molecular features of 17 patients with e-PV with those of 14 patients with essential thrombocythemia (ET) and 19 with PV. The results for e-PV were more similar to those for PV than for ET. In fact, patients with e-PV were characterized by an increase in the red cell parameters, splenomegaly (P<.05), and hepatomegaly (P=.038), together with hypercellular bone marrow due to increased erythropoiesis and granulopoiesis, associated with megakaryocytic hyperplasia, with pleomorphic aggregates (P<.001). The frequency of the JAK2V617F mutation was similar in e-PV (16 cases tested [100%]) and PV (18/19 [95%]) but was significantly lower (7/13 [54%]) in ET (P=.0007). We propose a diagnostic algorithm helpful to distinguish ET from the early prepolycythemic phase of PV.

[1]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[2]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[3]  P. Campbell,et al.  Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. , 2006, Blood.

[4]  J. Thiele,et al.  The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. , 2006, Seminars in thrombosis and hemostasis.

[5]  Alessia Moro,et al.  Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoieticbone marrow histology , 2006, Leukemia & lymphoma.

[6]  R. Levine,et al.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. , 2005, Blood.

[7]  M. Stratton,et al.  The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. , 2005, Blood.

[8]  P. Guglielmelli,et al.  Clinical implications of the JAK2 V617F mutation in essential thrombocythemia , 2005, Leukemia.

[9]  V. Diehl,et al.  Initial (Latent) Polycythemia vera with Thrombocytosis Mimicking Essential Thrombocythemia , 2005, Acta Haematologica.

[10]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[11]  M. Cazzola,et al.  Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.

[12]  H. Kreipe,et al.  The polycythaemia rubra vera‐1 gene is constitutively expressed by bone marrow cells and does not discriminate polycythaemia vera from reactive and other chronic myeloproliferative disorders , 2003, British journal of haematology.

[13]  E. Jaffe Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[14]  J. Jelinek,et al.  Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. , 2003, Blood.

[15]  J. Spivak Polycythemia vera: myths, mechanisms, and management. , 2002, Blood.

[16]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[17]  M. Lübbert,et al.  Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. , 2000, Blood.

[18]  E. Ikkala,et al.  Development of erythrocytosis in the course of essential thrombocythemia , 1999, Annals of Hematology.

[19]  S. Bilgrami,et al.  Polycythemia rubra vera. , 1995, Seminars in oncology.

[20]  C. Reid,et al.  The significance of endogenous erythroid colonies (EEC) in haematological disorders. , 1987, Blood reviews.

[21]  S. Schwartz Myeloproliferative Disorders , 1975, Annals of surgery.

[22]  L S KAPLOW,et al.  Cytochemistry of leukocyte alkaline phosphatase. Use of complex naphthol as phosphates in azo dyecoupling technics. , 1963, American journal of clinical pathology.

[23]  R. McClure,et al.  Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders , 2006, Leukemia.

[24]  J. Thiele,et al.  Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). , 2005, Histology and histopathology.

[25]  A. Tefferi,et al.  Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates. , 2005, Haematologica.

[26]  F. Girodon,et al.  Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. , 2004, Haematologica.

[27]  Ada Maria Florena,et al.  Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. , 2004, Haematologica.

[28]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[29]  S. Murphy Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. , 1999, Seminars in hematology.

[30]  L. Shih,et al.  Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. , 1994, Blood.

[31]  C. L. Conley Polycythemia vera. , 1990, JAMA.